Extended Data Fig. 2: Characterization of h1A6.2 and h1A6.2-LALA. | Nature Microbiology

Extended Data Fig. 2: Characterization of h1A6.2 and h1A6.2-LALA.

From: Broadly therapeutic antibody provides cross-serotype protection against enteroviruses via Fc effector functions and by mimicking SCARB2

Extended Data Fig. 2

a, Binding efficacies of h1A6.2 and h1A6.2-LALA to murine FcγRI, FcγRIIb, FcγRIII, FcγRIV or human FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa evaluated with binding ELISA. The values (n = 2) are expressed as the mean of two experiments. b and c, Binding efficacies of h1A6.2 and h1A6.2-LALA to EV71 (b) or CVA16 (c) evaluated with binding ELISA. The values (n = 3) are expressed as mean ± SD of three experiments. EC50 values were calculated with curves generated by nonlinear regression fitted.

Source data

Back to article page